PALI Palisade Bio, Inc.

NASDAQ
$1.03

Palisade Bio, Inc. (PALI) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.2% since its last earnings release on November 10, 2026.

Palisade Bio Missed Consensus Estimates
Tuesday, November 10, 2026 · 4:25 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:20 PM ET
Earnings Whisper
-
vs ($0.07)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Palisade Bio, Inc.

Palisade Bio is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.